Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Search Results

Filter
  • 1-10 of  374 results for ""mitogen-activated protein kinase""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.

  • Authors : Mahoney CL; Cancer Genome Project, Wellcome Trust Genome Campus, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.; Choudhury B

Subjects: Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/*genetics ; Lung Neoplasms/Lung Neoplasms/Lung Neoplasms/*genetics ; Mitogen-Activated Protein Kinase Kinases/Mitogen-Activated Protein Kinase Kinases/Mitogen-Activated Protein Kinase Kinases/*metabolism

  • Source: British journal of cancer [Br J Cancer] 2009 Jan 27; Vol. 100 (2), pp. 370-5.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.

  • Authors : Nakayama N; Departments of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Japan.; Nakayama K

Subjects: Mitogen-Activated Protein Kinase Kinases/Mitogen-Activated Protein Kinase Kinases/Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors ; Ovarian Neoplasms/Ovarian Neoplasms/Ovarian Neoplasms/*enzymology ; Ovarian Neoplasms/Ovarian Neoplasms/Ovarian Neoplasms/*genetics

  • Source: British journal of cancer [Br J Cancer] 2008 Dec 16; Vol. 99 (12), pp. 2020-8. Date of Electronic Publication: 2008 Nov 18.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

Record details

×
Academic Journal

Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.

  • Authors : Romerio F; Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA.; Riva A

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Interferon-alpha/Interferon-alpha/Interferon-alpha/*pharmacology ; Mitogen-Activated Protein Kinase 1/Mitogen-Activated Protein Kinase 1/Mitogen-Activated Protein Kinase 1/*metabolism

  • Source: British journal of cancer [Br J Cancer] 2000 Aug; Vol. 83 (4), pp. 532-8.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

  • Authors : Menu E; Department of Hematology and Immunology, Vrije Universiteit Brussel - VUB, 1090 Brussels, Belgium.; Kooijman R

Subjects: Protein Serine-Threonine Kinases*; Chemotaxis/Chemotaxis/Chemotaxis/*drug effects ; Insulin-Like Growth Factor I/Insulin-Like Growth Factor I/Insulin-Like Growth Factor I/*pharmacology

  • Source: British journal of cancer [Br J Cancer] 2004 Mar 08; Vol. 90 (5), pp. 1076-83.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium:

Record details

×
  • 1-10 of  374 results for ""mitogen-activated protein kinase""